@ARTICLE{
author={Petzer Andreas L,Fong Dominic,Lion Thomas,Dyagil Irina,Masliak Zvenyslava,Bogdanovic Andrija D,Griskevicius Laimonas,Lejniece Sandra,Goranov Stefan,Gercheva Liana,Stojanovic Aleksandar,Peytchev Dontcho,Tzvetkov Nikolay,Griniute Rasa,Oucheva Radka,Grubinger T,Kwakkelstein Marthin,Rancati Francesca,Gastl Guenther A,Wolf Dominik},
year={2011},
title={Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG phase III "ISTAHIT" trial},
journal={ONKOLOGIE},
volume={34},
number={},
pages={264-264},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Petzer Andreas L,Wolf Dominik,Fong Dominic,Lion Thomas,Dyagil Irina,Masliak Zvenyslava,Bogdanovic Andrija D,Griskevicius Laimonas,Lejniece Sandra,Goranov Stefan,Gercheva Liana,Stojanovic Aleksandar,Peytchev Dontcho,Tzvetkov Nikolay,Griniute Rasa,Oucheva Radka,Ulmer Hanno,Kwakkelstein Marthin,Rancati Francesca,Gastl Guenther A},
year={2010},
title={High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study},
journal={HAEMATOLOGICA-THE HEMATOLOGY JOURNAL},
volume={95},
number={6},
pages={908-913},
document_type={Article},
} 

@ARTICLE{
author={Petzer Andreas L,Wolf Dominik,Fong Dominic,Lion Thomas,Dyagil Irina,Masliak Zvenyslava,Boskovic Darinka V,Griskevicius Laimonas,Lejniece Sandra,Spasov Emil,Gercheva Liana,Stojanovic Aleksandar,Peytchev Dontcho,Tzvetkov Nikolay,Griniute Rasa,Stanchev Atanas,Kwakkelstein Martin,Ulmer Hanno,Gastl Guenther A},
year={2007},
title={Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Results from the first planned interim analysis (CELSG-CML 11 ISTAHIT study)},
journal={BLOOD},
volume={110},
number={11},
pages={317A-317A},
document_type={Meeting Abstract},
}